Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M

Journal of Medicinal Chemistry

Volumn 49, Issue 4, 2006, Pages 1379-1387

  Kovalevsky, Andrey Yu ^a   Tie, Yunfeng ^a   Liu, Fengling ^a   Boross, Peter I ^a,b   Wang, Yuan Fang ^a   Leshchenko, Sofiya ^c   Ghosh, Arun K ^b   Harrison, Robert W ^a   Weber, Irene T ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ASPARAGINE; DARUNAVIR; ENZYME VARIANT; PROTEINASE; PROTEINASE INHIBITOR; WATER;

ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME STRUCTURE; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR INTERACTION; MUTANT; MUTATION; STRUCTURE ACTIVITY RELATION; WILD TYPE;

CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, VIRAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HYDROGEN BONDING; HYDROPHOBICITY; INDINAVIR; KINETICS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTATION; SULFONAMIDES;

EID: 33144466093     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050943c     Document Type: Article

References (44)

1. Barlett, J. A.; DeMasi, R.; Quinn, J.; Moxham, C.; Rousseau, F. Overview of the Effectiveness of Triple Combination Therapy in Antiretroviral-Naïve HIV-1 Infected Adults. AIDS 2001, 15, 1369-1377.
2. Gulick, R. M.; Mellors, J. W.; Havlir, D.; Eron, J. J.; Meibohm, A.; Condra, J. H.; Valentine, F. T.; McMahon, D.; Gonzalez, C.; Jonas, L.; Emini, E. A.; Chodakewitz, J. A.; Isaacs, R.; Richman, D. D. 3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine. Ann. Intern. Med. 2000, 133, 35-39.
3. De Clercq, E. New Approaches toward Anti-HIV Chemotherapy. J. Med. Chem. 2005, 48, 1-17.
4. Wlodawer, A.; Vondrasek, J. Inhibitors of HIV-1 Protease: A Major Success of Structure-Assisted Drug Design. Annu. Rev. Biophys. Biomol. Struct. 1998, 27, 249-284.
5. Wlodawer, A.; Gustchina, A. Structural and Biochemical Studies of Retroviral Proteases. Biochim. Biophys. Acta 2000, 1477, 16-34.
6. Menedez-Arias, L. Targeting HIV: Antiretroviral Therapy and Development of Drug Resistance. Trends Pharmacol. Sci. 2002, 23, 381-388.
7. Barbaro, G.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Highly Active Antiretroviral Tharepy: Current State of the Art, New Agents and Their Pharmacological Interactions Useful for Improving Therapeutic Outcome. Curr. Pharm. Des. 2005, 11, 1805-1844.
8. Sax, P. E. Do New Protease Inhibitors Offer Improved Management Options? J. AIDS 2004, 35, S22-S34.
9. Hertogs, K.; Bloor, S.; Kemp, S. D.; Van den Eynde, C.; Alcorn, T. M.; Pauwels, R.; Van Houtte, M.; Staszewski, S.; Miller, V.; Larder, B. A. Phenotypic and Genotypic Analysis of Clinical HIV-1 Isolates Reveals Extensive Protease Inhibitor Cross-Resistance: A Survey of Over 6000 Samples. AIDS 2000, 14, 1203-1210.
10. Wu, T. D.; Schiffer, C. A.; Gonzales, M. J.; Taylor, J.; Kantor, R.; Chou, S.; Israelski, D.; Zolopa, A. R.; Fessel, W. J.; Shafer, R. W. Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease Following Different Protease Inhibitor Treatments. J. Virol. 2003, 4836-4847.
11. Ohtaka, H.; Freire, E. Adaptive Inhibitors of the HIV-1 Protease. Prog. Biophys. Mol. Biol. 2005, 88, 193-208.
12. Koh, Y.; Makata, H.; Maeda, K.; Ogata, H.; Bilcer, G.; Devasamudram, T.; Kincaid, J. F.; Boross, P.; Wang, Y.-F.; Tie, Y.; Volarath, P.; Gaddis, L.; Harrison, R. W.; Weber, I. T.; Ghosh, A. K.; Mitsuya, H. Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) TMC-114 (TMC-114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus in Vitro, Antimicrob, Agents Chemother. 2003, 3123-3129.
13. Surleraux, D. L. N. G.; Tahri, A.; Verschueren, W. G.; Pille, G. M. E.; de Kock, H. A.; Jonckers, T. H. M.; Peeters, A.; De Meyer, S.; Azijn, H.; Pauwels, R.; de Bethune, M.-P.; King, N. M.; Prabu-Jeyabalan, M.; Schiffer, C. A.; Wigerinck, P. B. T. P. Discovery and Selection of TMC-114, a Next Generation HIV-1 Protease Inhibitor. J. Med. Chem. 2005, 48, 1813-1822.
14. De Meyer, S.; Azijn, H.; Surleraux, D.; Jochmans, D.; Tahri, A.; Pauwels, R.; Wigerinck, P.; de Bethune, M.-P. TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates. Antimicrob. Agents Chemother. 2005, 2314-2321.
15. Shurtleff, A. C. TMC-114 (Tibotec). Curr. Opin. Invest. Drugs 2004, 5, 879-886. See also articles published on clinialtrials.gov.
16. Tie, Y.; Boross, P. I.; Wang, Y.-F.; Gaddis, L.; Hussain, A. K.; Leshchenko, S.; Ghosh, A. K.; Louis, J. M.; Harrison, R. W.; Weber, I. T. High-Resolution Crystal Structures of HIV-1 Protease with a Potent Non-Peptide Inhibitor (TMC-114) Active against Multi-Drug-Resistant Clinical Strains. J. Mol. Biol. 2004, 338, 341-352.
17. King, N. M.; Prabu-Jeyabalan, M.; Nalivaika, E. A.; Wigerinck, P.; de Bethune, M.-P.; Schiffer, C. A. Structural and Thermodynamic Basis for the Binding of TMC-114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor. J. Virol. 2004, 12012-12021.
18. Velazquez-Campoy, A.; Kiso, Y.; Freire, E. The Binding Energetics of First and Second Generation HIV-1 Protease Inhibitors: Implications for Drug Design. Arch. Biochim. Biophys. 2001, 390, 169-175.
19. Velazquez-Campoy, A.; Luque, I.; Freire, E. The Application of Thermodynamic Methods in Drug Design. Thermochim. Acta 2001, 380, 217-227.
20. Clemente, J. C.; Moose, R. E.; Hemrajani, R.; Whitford, L. R. S.; Govindasamy, L.; Reutzel, R.; McKenna, R.; Agbandje-McKenna, M.; Goodenow, M. M.; Dunn, B. M. Comparing the Accumulation of Active- and Nonactive-Site Mutations in the HIV-1 Protease. Biochemistry 2004, 43, 12141-12151.
21. Mahalingam, B.; Wang, Y.-F.; Boross, P. I.; Tozser, J.; Louis, J. M.; Harrison, R. W.; Weber, I. T. Crystal Structures of HIV Protease V82A and L90M Mutants Reveal Changes in the Indinavir-Binding Site. Eur. J. Biochem. 2004, 271, 1516-1524.
22. Rhee, S.-Y.; Gonzales, M. J.; Kantor, R.; Betts, B. J.; Ravela, J.; Shafer, R. W. Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database. Nucleic Acids Res. 2003, 31, 298-303.
23. Jarvis, B.; Faulds, D. Nelfinavir: A Review of Its Therapeutic Efficacy in HIV Infection. Drugs 1998, 56, 147-167.
24. Mahalingam, B.; Louis, J. M.; Reed, C. C.; Adomat, J. M.; Krouse, J.; Wang, Y.-F.; Harrison, R. W.; Weber, I. T. Structural and Kinetic Analysis of Drug Resistant Mutants of HIV-1 Protease. Eur. J. Biochem. 1999, 263, 238-245.
25. Mahalingam, B.; Louis, J. M.; Hung, J.; Harrison, R. W.; Weber, I. T. Structural Implications of Drug-Resistant Mutants of HIV-1 Protease: High-Resolution Crystal Structures of the Mutant Protease/Substrate Analogue Complexes. Proteins 2001, 43, 455-464.
26. Tisdale, M.; Myers, R.; Randall, S.; Maguire, M.; Ait-Khaled, M.; Elston, R.; Snowden, W. Resistance of the HIV Protease Inhibitor Amprenavir in Vitro and in Clinical Studies. Clin. Drug Invest. 2000, 20, 267-285.
27. Johnson, V. A.; Brun-Vezinet, F.; Clotet, B.; Conway, B.; D'Aquila, R. T.; Demeter, L. M.; Kuritzkes, D. R.; Pillay, D.; Schapiro, J. M.; Telenti, A.; Richman, D. D. Update of the Drug Resistance Mutations in HIV-1. Top. HIV Med. 2004, 12, 119-124.
28. Lam, P. Y. S.; Jahdav, P. K.; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, Y. N.; Chang, C.-H.; Weber, P. C.; Jackson, D. A.; Sharpe, T. R.; Erickson-Viitanen, S. Rational Design of Potent. Bioavalable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors. Science 1994, 263, 380-384.
29. Lam, P. Y. S.; Ru, Y.; Jahdav, P. K.; Aldrich, P. E.; DeLucca, G. V.; Eyermann, C. J.; Chang, C.-H.; Emmett, G.; Holler, E. R.; Daneker, W. F.; Li, L.; Confalone, P. N.; McHugh, R. J.; Han, Q.; Li, R.; Markwalder, J. A.; Seitz, S. P.; Sharpe, T. R.; Bacheler, L. T.; Rayner, M. M.; Klabe, R. M.; Shum, L.; Winslow, D. L.; Korhauser, D. M.; Jackson, D. A.; Erickson-Viitanen, S.; Hodge, C. N. Cyclic HIV Protease Inhibitors: Synthesis, Conformational Analysis, P2/P2′ Structure-Activity Relationship, and Molecular Recognition of Cyclic Ureas. J. Med. Chem. 1996, 39, 3514-3525.
30. Hodge, C. N.; Aldrich, P. E.; Bacheler, L. T.; Chang, C. H.; Eyermann, C. J.; Garber, S.; Grubb, M.; Jackson, D. A.; Jadhav, P. K.; Korant, B.; Lam, P. Y.; Maurin, M. B.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Reid, C.; Sharpe, T. R.; Shum, L.; Winslow, D. L.; Erickson-Viitanen, S. Improved Cyclic Urea Inhibitors of the HIV-1 Protease: Synthesis, Potency, Resistance Profile, Human Pharmacokinetics and X-ray Crystal Structure of DMP450. Chem. Biol. 1996, 3, 301-314.
31. Steiner, T. C-H⋯O Hydrogen Bonding in Crystals. Crystallogr. Rev. 1996, 6, 1-51;
32. Wahl, M. C.; Sundaralingam, M. C-H⋯O Hydrogen Bonding in Biology. Trends Biochem. Sci. 1997, 22, 97-102.
33. Hong, L.; Zhang, X. C.; Hartsuck, J. A.; Tang, J. Crystal Structure of an in vivo HIV-1 Protease Mutant in Complex with Saquinavir: Insight into the Mechanisms of Drug Resistance. Protein Sci. 2000, 9, 1898-1904.
34. Liu, F.; Boross, P. I.; Wang, Y.-F.; Tozser, J.; Louis, J. M.; Harrison, R. W.; Weber, I. T. Kinetics, Dimer Stability, and High Resolution Crystal Structures of HIV-1 Protease Drug Resistant Variants L24I, I50V, and G73S. J. Mol. Biol. 2005, 354, 789-800.
35. Louis J. M.; Clore, G. M.; Gronenborn, A. M. Autoprocessing of HIV-1 Protease Is Tightly Coupled to Protein Folding. Nat. Struct. Biol. 1999, 6, 868-875.
36. Bagossi, P.; Kadas, J.; Miklossy, G.; Boross, P.; Weber, I. T.; Tozser, J. Development of a Microtiter Plate Fluorescent Assay for Inhibition Studies on the HTLV-1 and HIV-1 Proteinases. J. Virol. Met. 2004, 119, 87-93.
37. Maibaum, J.; Rich, D. H. Inhibition of Porcine Pepsin by Two Substrate Analogues Containing Staline: The Effect of Histidine at the P2 Subsite on the Inhibition of Aspartic Proteinases. J. Med. Chem. 1988, 31, 625-629.
38. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data in Oscillation Mode. Met. Enzymol. 1997, 276, 307-326.
39. Collaborative Computational Project, Number 4. The CCP4 Suite: Programs for Protein Crystallography. Acta Crystallogr. D 1994, 50, 760-763;
40. Potterton, E.; Briggs, P.; Turkenburg, M.; Dodson, E. A Graphical User Interface to the CCP4 Program Suite. Acta Crystallogr. D 2003, 59, 1131-1137.
41. Sheldrick, G. M.; Schneider, T. R. High-Resolution Refinement. Met. Enzymol. 1997, 277, 319-343.
42. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeldgaard, M. Improved Methods for Building Protein Models in Electron Density Maps and the Location of Errors in These Models. Acta Crystallogr. A 1991, 47, 110-119.
43. Ferro, D. R.; Hermans, J. A Different Best Rigid-Body Molecular Fit Routine. Acta Crystallogr. A 1977, 33, 345-347.
44. Kraulis, P. J. MOLSCRIPT: A Program to Produce Both Detailed and Schematic Plots of Protein Structures. J. Appl. Crystallogr. 1991, 24, 946-950.